Welcome to our dedicated page for MEDIPHARM LABS news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on MEDIPHARM LABS stock.
MediPharm Labs Corp (MEDIF) is a pharmaceutical company specializing in precision-based cannabinoids. With GMP certification from ANVISA, FDA, EU, and TGA, MediPharm leads in pharmaceutical cannabinoids. They manufacture authorized medical cannabis products in compliance with strict regulations, including products for the Brazilian market under Resolution 327/19. By acquiring VIVO Cannabis, MediPharm expanded its reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.
Rhea-AI Summary
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) will release its first quarter financial results for the period ended March 31, 2024, on Wednesday, May 15, 2024. The company specializes in precision-based cannabinoids and will host a conference call to discuss the financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
MediPharm Labs Corp. releases its full year and fourth quarter financial results for 2023, showing a 50% improvement in annual revenue and adjusted EBITDA. The company specializes in precision-based cannabinoids and hosted a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
-
Rhea-AI Summary
MediPharm Labs Corp. (MEDIF) reports a 50% increase in annual revenue to $33M and a 50% improvement in Adjusted EBITDA for the full year 2023. The company shows significant growth in gross profit, a strong balance sheet, and expansion in international medical cannabis markets. MediPharm's focus on profitability includes cost reductions and improving product mix, positioning them for a profitable future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
Rhea-AI Summary
German federal states have voted to decriminalize personal cannabis cultivation and use, with legislation effective from April 1, 2024. MediPharm Labs Corp. (MEDIF) applauds the move, as it removes medical cannabis from the narcotic list, easing patient access barriers and boosting its German business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
-
Rhea-AI Summary
MediPharm Labs Corp. announces the release of its full-year and fourth-quarter financial results for the period ended December 31, 2023. The executive management team will host a conference call and audio webcast on March 27, 2024, to discuss the financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.37%
Tags
-
Rhea-AI Summary
MediPharm Labs has received a GMP certificate from the Brazilian Health Regulatory Agency, ANVISA, making it the first pharmaceutical cannabis company in North America to do so. This certification allows the company to manufacture both active pharmaceutical ingredients (API) and end products for medical cannabis patients in Brazil. With a population of 215 million, Brazil has seen a 480% increase in medical cannabis prescriptions in 2022, indicating a significant market opportunity. The certification strengthens MediPharm's global position as a leader in the development and production of pharmaceutical cannabinoids, providing access to the Brazilian medical cannabis market and facilitating entry into additional global markets. The Brazilian medical cannabis market is expected to reach $380 million CAD in 2025, and MediPharm Labs currently manufactures two medical cannabis products with full ANVISA product authorization under Brazil's Resolution 327/19. The company has also entered into a supply agreement with a top-tier generic pharmaceutical company in Brazil, further expanding its market reach. The GMP certification was obtained after a rigorous inspection of MediPharm's manufacturing capabilities and quality management system, resulting in a compliant GMP status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced changes to its Board of Directors and employee stock issuance, including the resignation of a founding board member and the grant of 15.48 million stock options and 16.09 million restricted share units. The Company will continue with five board members, reflecting an overall right sizing of the business undertaken in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced its financial results for Q3 2023, achieving higher gross margins and moving closer to profitability. The company settled a customer dispute for $9M, recorded a gross profit of $2.4M, improved adjusted EBITDA by 53%, and strengthened its balance sheet with $13M cash and less than $3M debt. Additionally, the company made significant progress in international medical cannabis growth and solidified its leadership in the cannabis-based pharmaceutical industry. Management's focus on margins, cost reductions, and profitability has positioned the company to make strategic investments for revenue growth, with M&A opportunities on the horizon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
-
Rhea-AI Summary
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its Q3 financial results for the three and nine month periods ended September 30, 2023 on November 14, 2023. The executive team will host a conference call and webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
News
Rhea-AI Summary
MediPharm Labs receives $7.27 million in cash and non-cash elements from settlement agreement with Tilray, strengthening the company's balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
FAQ
What is the current stock price of MEDIPHARM LABS (MEDIF)?
The current stock price of MEDIPHARM LABS (MEDIF) is $0.043572 as of December 24, 2024.
What is the market cap of MEDIPHARM LABS (MEDIF)?
The market cap of MEDIPHARM LABS (MEDIF) is approximately 20.5M.
What certifications does MediPharm Labs Corp hold?
MediPharm Labs Corp holds GMP certification from ANVISA, FDA, EU, and TGA.
What products does MediPharm Labs manufacture?
MediPharm Labs manufactures authorized medical cannabis products under strict regulatory compliance, including products for the Brazilian market.
What was the significance of acquiring VIVO Cannabis?
The acquisition of VIVO Cannabis expanded MediPharm's reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.
When was MediPharm Labs Corp founded?
MediPharm Labs Corp was founded in 2015.
What is the core business of MediPharm Labs Corp?
The core business of MediPharm Labs Corp is to specialize in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and derivative products.
What is the current financial position of MediPharm Labs Corp?
MediPharm Labs Corp is in a strong financial position, with significant revenue growth and improving Adjusted EBITDA.
In which markets does MediPharm Labs operate?
MediPharm Labs operates in domestic and international medical markets, including Canada, Australia, Germany, and Brazil.
What regulatory certifications did MediPharm Labs receive in 2021?
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada.
What is the significance of MediPharm Labs' GMP certification?
MediPharm Labs' GMP certification ensures adherence to strict manufacturing processes and facilitates access to global markets.
What is the expected growth of the Brazilian medical cannabis market?
The Brazilian medical cannabis market is expected to reach $380 million CAD in 2025.
MEDIPHARM LABS CORP
OTC:MEDIF
MEDIF Rankings
MEDIF Stock Data
20.54M
382.53M
4.45%
0.71%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Barrie